Literature DB >> 11307741

Smoking-related interstitial lung diseases: a concise review.

J H Ryu1, T V Colby, T E Hartman, R Vassallo.   

Abstract

Interstitial lung diseases (also known as diffuse infiltrative lung diseases) are a heterogeneous group of parenchymal lung disorders of known or unknown cause. These disorders are usually associated with dyspnoea, diffuse lung infiltrates, and impaired gas exchange. The majority of interstitial lung diseases are of unknown cause. Known causes of interstitial lung disease include inhalation of organic and inorganic dusts as well as gases or fumes, drugs, radiation, and infections. This review summarizes the clinical, radiological, and histopathological features of four interstitial lung disorders that have been linked to smoking. These disorders include desquamative interstitial pneumonia, respiratory bronchiolitis-associated interstitial lung disease, pulmonary Langerhans' cell histiocytosis, and idiopathic pulmonary fibrosis. Available evidence suggests most cases of desquamative interstitial pneumonia, respiratory bronchiolitis-associated interstitial lung disease, and pulmonary Langerhans' cell histiocytosis are caused by cigarette smoking in susceptible individuals. Smoking cessation should be a main component in the initial therapeutic approach to smokers with these interstitial lung diseases. In addition, smoking appears to be a risk factor for the development of idiopathic pulmonary fibrosis.

Entities:  

Mesh:

Year:  2001        PMID: 11307741     DOI: 10.1183/09031936.01.17101220

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  57 in total

1.  Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 40-2002. A 56-year-old man with rapidly worsening dyspnea.

Authors:  Michelle Ng Gong; Eugene J Mark
Journal:  N Engl J Med       Date:  2002-12-26       Impact factor: 91.245

2.  The "dirty chest"--correlations between chest radiography, multislice CT and tobacco burden.

Authors:  J Kirchner; J P Goltz; F Lorenz; A Obermann; E M Kirchner; R Kickuth
Journal:  Br J Radiol       Date:  2011-09-21       Impact factor: 3.039

3.  [Interstitial lung diseases (ILD) in smokers: spectrum in high resolution computed tomography (HRCT)].

Authors:  K Marten-Engelke
Journal:  Radiologe       Date:  2013-09       Impact factor: 0.635

Review 4.  [Therapy for idiopathic interstitial pneumonias: steroids--and what else?].

Authors:  A Prasse; J Müller-Quernheim
Journal:  Internist (Berl)       Date:  2006-12       Impact factor: 0.743

5.  [A 47-year-old patient with longstanding nicotine abuse, increasing dyspnea on exertion and lower and peripheral lung predominant ground-glass opacities].

Authors:  P Heiss; C Kundel; C Schulz; S Feuerbach; O W Hamer
Journal:  Radiologe       Date:  2009-05       Impact factor: 0.635

6.  Long-Term Sequelae of Smoking and Cessation in Spontaneously Hypertensive Rats.

Authors:  Ching-Wen Wu; Tammy Yau; Ciara C Fulgar; Savannah M Mack; Alina M Revilla; Nicholas J Kenyon; Kent E Pinkerton
Journal:  Toxicol Pathol       Date:  2019-12-24       Impact factor: 1.902

7.  Smoking-related idiopathic interstitial pneumonia.

Authors:  Kevin R Flaherty; Charlene Fell; Marie-Christine Aubry; Kevin Brown; Thomas Colby; Ulrich Costabel; Teri J Franks; Barry H Gross; David M Hansell; Ella Kazerooni; Dong Soon Kim; Talmadge E King; Masanori Kitachi; David Lynch; Jeff Myers; Sonoko Nagai; Andrew G Nicholson; Venerino Poletti; Ganesh Raghu; Moises Selman; Galen Toews; William Travis; Athol U Wells; Robert Vassallo; Fernando J Martinez
Journal:  Eur Respir J       Date:  2014-07-25       Impact factor: 16.671

Review 8.  Interstitial lung disease: the diagnostic role of bronchoscopy.

Authors:  Jad Kebbe; Tony Abdo
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

9.  Clinical characteristics in patients with asymmetric idiopathic pulmonary fibrosis.

Authors:  Sean J Callahan; Meng Xia; Susan Murray; Kevin R Flaherty
Journal:  Respir Med       Date:  2016-08-31       Impact factor: 3.415

10.  [Pulmonary fibrosis].

Authors:  A Prasse; J U Holle; J Müller-Quernheim
Journal:  Internist (Berl)       Date:  2010-01       Impact factor: 0.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.